艾昆纬-阿布扎比NIPT景观-了解无创产前检测（NIPT）的当前使用情况、挑战和扩大使用的潜力（英）

White PaperThe Landscape of NIPT in Abu DhabiUnderstanding the current use, challenges and potential of expanding use of Non-Invasive Prenatal Testing (NIPT) B | The Landscape of NIPT in Abu DhabiRestriction on disclosure statement© 2025. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.All trademarks, trade names, product names, graphics, and logos of IQVIA, Quintiles, or IMS Health contained herein are trademarks or registered trademarks of IQVIA Holdings, Inc., or its subsidiary, as applicable, in the United States and/or other countries. All other trademarks, trade names, product names, graphics and logos contained herein are the property of their respective owners. The use or display of other parties’ trademarks, trade names, product names, graphics or logos is not intended to imply, and should not be construed to imply a relationship with, or endorsement or sponsorship of IQVIA Holdings, Inc., or its subsidiaries by such other party.Table of contentsExecutive summary 1Introduction 3Current prenatal testing landscape 4Non-Invasive Prenatal Testing (NIPT) 5NIPT adoption across the globe 6The prenatal testing landscape and NIPT adoption in the Abu Dhabi 7Stakeholder perspectives on NIPT in Abu Dhabi 10Recommendations for expanding NIPT in Abu Dhabi 11Conclusion 14Appendix 15Glossary and abbreviations 15Acknowledgement 15References 16About the authors 19About IQVIA 20About Illumina 20Table of contents1 | The Landscape of NIPT in Abu DhabiExecutive summaryChromosomal abnormalities pose significant challenges for prenatal healthcare globally, leading to conditions such as Down syndrome (Trisomy 21), Edward’s syndrome (Trisomy 18), and Patau’s syndrome (Trisomy 13), which can result in severe cognitive and physical disabilities1. While traditional prenatal screening methods, such as first-trimester combined tests and amniocentesis, have long been used to detect these conditions, they often come with limitations. These methods can result in high false-positive rates, and invasive procedures carry a risk of miscarriage. This has prompted many countries to adopt Non-Invasive Prenatal Testing (NIPT), a safer, highly accurate alternative for detecting chromosomal abnormalities through a simple maternal blood test. Globally, NIPT has been widely accepted, with countries such as the United States, Germany, and the Netherlands2, 4, 5, 7 integrating it into standard prenatal care. However, its accessibility and usage still vary depending on national healthcare policies and insurance coverage.In Abu Dhabi, the healthcare system is world-class, providing high-quality maternal care that is comparable to Western countries. In July 2024, the Department of Health (DOH) updated its guidelines to include NIPT as a recommended test for high-risk pregnancies,3 such as those in women over 35 or with a family history of chromosomal abnormalities. However, despite the availabil